Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Discovery of a star sensitive to the spin of Sagittarius A.
Journal: Nature
Published: January 16, 2026
Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study.
Journal: The Lancet. Rheumatology
Published: June 15, 2025
Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis.
Journal: Rheumatology and therapy
Published: February 24, 2025
Impact of Delay of Treatment With Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Journal: ACR open rheumatology
Published: July 23, 2024
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial.
Journal: Rheumatology (Oxford, England)
Published: March 05, 2024
Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial.
Journal: Arthritis care & research
Published: October 10, 2023
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: April 25, 2023
Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study.
Journal: The Lancet. Rheumatology
Published: November 29, 2022
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Journal: Annals of the rheumatic diseases
Published: October 12, 2021
Patient's experience of psoriatic arthritis: a conceptual model based on qualitative interviews.
Journal: RMD open
Published: June 03, 2020
Model-Based Meta-Analysis Compares DAS28 Rheumatoid Arthritis Treatment Effects and Suggests an Expedited Trial Design for Early Clinical Development.
Journal: Clinical pharmacology and therapeutics
Published: April 23, 2020
Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants.
Journal: British journal of clinical pharmacology
Published: July 31, 2019
Last Updated: 09/26/2026